A single-center, retrospective analysis on a cohort of ipilimumab/nivolumab in patients with metastatic or unresectable melanoma
Latest Information Update: 01 Aug 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 01 Aug 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology